A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity

A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity

Sang Hee Park,1 Xue Han,2 Francis Lobo,2 Sakina Nanji,1 Dipen Patel1 1Modeling and Meta-Analysis, Pharmerit International, Bethesda, MD, USA; 2WW HEOR Markets-US, Bristol-Myers Squibb Company, Lawrenceville, NJ, USACorrespondence: Xue HanBristol-Myers Squibb Company, 3401 Princeton Pike, Lawrencevil...

Full description

Bibliographic Details
Main Authors: Park SH, Han X, Lobo F, Nanji S, Patel D
Format: Article
Language:English
Published: Dove Medical Press 2020-10-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
positive shared epitope (se+)
anti-citrullinated protein antibodies (acpa)
anti-cyclic citrullinated peptide (anti-ccp)
rheumatoid factor (rf)
biomarker
seropositive
Online Access:https://www.dovepress.com/a-cost-per-responder-model-for-abatacept-versus-adalimumab-among-rheum-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/a-cost-per-responder-model-for-abatacept-versus-adalimumab-among-rheum-peer-reviewed-article-CEOR

Similar Items